The treatment, Ibrance, was being tested along with the standard of care for early breast cancer in men and women, against standard of care alone, the company said on Friday. The study was broadly seen to have a high probability of success readout, but the early failure represents a meaningful setback for Pfizer, JP Morgan analysts said in a note, cutting its price target on the stock by $1 to $37.

from Yahoo Finance https://ift.tt/36NeQSD

Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Heidi Chung discuss the market action for Tesla.

from Yahoo Finance https://ift.tt/2ZWhkg3

Yahoo Finance’s Jared Blikre breaks down the latest on U.S, China relations.

from Yahoo Finance https://ift.tt/2zPZEYO